Scholarlink

<p>Terbinafine is an orally and topically active allylamine antifungal agent with fungistatic and fungicidal action. Its mechanism of action is the competitive inhibition of squalene epoxidase which leads to squalene accumulation and ergosterol depletion in the cell membrane. Clinically relevant pathogens can include but are not limited to: <i>Aspergillus</i> spp., <i>Candida</i> spp., <i>Blastomyces dermatitidis</i>,<i> Histoplasma capsulatum</i>,<i> Emydomyces testavorans</i>,<i> Ophidiomyces ophiodiicola</i>, and <i>Batrachochytrium dendrobatidis</i>. Terbinafine is an antifungal drug that has been used successfully in humans with few adverse effects. It is not licensed in the United States for systemic use in veterinary medicine but is routinely used in an extra label manner to treat fungal infections. Terbinafine has been well tolerated in domesticated and non-domesticated animals that have been studied. The studies that are available suggest that species differences exist in pharmacokinetics and further research is necessary to establish recommended doses in individual species. Due to the variation, terbinafine should be investigated on a species-by-species basis to determine its effective and safe use, thus ensuring the wellbeing of animals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemic use of terbinafine in veterinary medicine: A review of pharmacokinetic studies

  • 期刊论文

  • 发表日期：

    2026年4月29日

查看全文
  • Lainey Harvill,
  • Sherry Cox

摘要

Terbinafine is an orally and topically active allylamine antifungal agent with fungistatic and fungicidal action. Its mechanism of action is the competitive inhibition of squalene epoxidase which leads to squalene accumulation and ergosterol depletion in the cell membrane. Clinically relevant pathogens can include but are not limited to: Aspergillus spp., Candida spp., Blastomyces dermatitidis, Histoplasma capsulatum, Emydomyces testavorans, Ophidiomyces ophiodiicola, and Batrachochytrium dendrobatidis. Terbinafine is an antifungal drug that has been used successfully in humans with few adverse effects. It is not licensed in the United States for systemic use in veterinary medicine but is routinely used in an extra label manner to treat fungal infections. Terbinafine has been well tolerated in domesticated and non-domesticated animals that have been studied. The studies that are available suggest that species differences exist in pharmacokinetics and further research is necessary to establish recommended doses in individual species. Due to the variation, terbinafine should be investigated on a species-by-species basis to determine its effective and safe use, thus ensuring the wellbeing of animals.